Cardiac Dimensions has announced it has expanded its previously announced financing round to $28.5 million with the addition of $8.5 million.

Cardiac Dimensions, based in Kirkland, Wash., develops interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation.

For the round, Michigan-based VC firm Arboretum Ventures joined investors from Australia, the United States and Canada that includes M.H. Carnegie & Co. and Lumira Capital.

Cardiac Dimensions indicated the funding will used to support the completion of the company’s REDUCE FMR clinical trial, a blinded, randomized clinical trial in the field of functional mitral regurgitation. as well as accelerating and expanding the company’s commercial expansion plans.